Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

2021157 citationsJournal Articlehybrid Open Access

Authors

Nathan Fowler · The University of Texas MD Anderson Cancer Center

Felipe Samaniego · The University of Texas MD Anderson Cancer Center

Wojciech Jurczak · The Maria Sklodowska-Curie National Research Institute of Oncology

Nilanjan Ghosh · Levine Cancer Institute

Enrico Derenzini · University of Milan

James A. Reeves · Sarah Cannon

Wanda Knopińska‐Posłuszny

Abstract

Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event-related discontinuations.

Topics & Keywords

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Cutaneous lymphoproliferative disorders research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 15, pp. 1609-1618

DOI: 10.1200/jco.20.03433

Field-Weighted Citation Impact: 19.46